Why Axsome Therapeutics, Inc. (AXSM) Stock Fell 5.8% on Oct 13, 2026
The clearest new catalyst: Slower-than-expected product prescription rollout.
Why did AXSM stock fall?
Axsome Therapeutics fell 5.8% to $156.32 on October 13, 2026, extending a multi-week losing streak driven by prescription rollout concerns for flagship products, technical overselling, and sector-wide pressure on growth biotech amid macro headwinds. The decline reflects both company-specific commercial challenges and broader risk-off sentiment ahead of the company's Q3 earnings report scheduled for November 2.
- Slower-than-expected product prescription rollout: Market sentiment has been pressured by slower or lower-than-expected early prescription trends for flagship products like Auvelity, prompting financial firms to adjust price targets downward despite maintaining long-term bullish ratings.
- Technical overselling and momentum selling: As the stock pulled back sharply from earlier 2026 highs, technical indicators flagged the stock as heavily oversold, triggering automated and momentum-driven selling pressure.
- Extended losing streak and position rebalancing: October 13 marked the continuation of a multi-day sell-off extending past a dozen straight sessions with the stock down over 15% across the month, as investors rebalanced positions ahead of Q3 2026 earnings.
- Sector-wide biotech pullback amid macro headwinds: Growth-oriented biotech stocks faced pressure from surging oil prices and rising Treasury yields, creating a broader risk-off environment for equities.
Initial detection
BestStocks first flagged AXSM intraday on Oct 13, 2026; this analysis was finalized after the close using the confirmed −5.8% session move and additional catalyst research.
Show the initial intraday note
Axsome Therapeutics extended a multi-day losing streak as part of a sector-wide pullback in growth-oriented biotech stocks amid macro headwinds—specifically surging oil prices and rising Treasury yields pressuring risk-on equities. AXSM fell 4.95% to $157.79 intraday on volume 1.49x the 120-minute average, contributing to a cumulative drop of roughly 14% over an 11-session stretch through mid-October 2026.
What to watch next: Axsome's third-quarter 2026 earnings release on November 2, 2026; consensus EPS estimate is −$0.55. Monitor Auvelity prescription-volume trends and any guidance revisions as key catalysts for sentiment reversal.
Frequently asked questions
Why did Axsome Therapeutics, Inc. (AXSM) stock fall on Oct 13, 2026?
Axsome Therapeutics fell 5.8% to $156.32 on October 13, 2026, extending a multi-week losing streak driven by prescription rollout concerns for flagship products, technical overselling, and sector-wide pressure on growth biotech amid macro headwinds. The decline reflects both company-specific commercial challenges and broader risk-off sentiment ahead of the company's Q3 earnings report scheduled for November 2.
How much did AXSM stock fall on Oct 13, 2026?
AXSM fell 5.8% during the Oct 13, 2026 trading session.
What were the main drivers behind AXSM's move?
Slower-than-expected product prescription rollout; Technical overselling and momentum selling; Extended losing streak and position rebalancing; Sector-wide biotech pullback amid macro headwinds.